Ixazomib for Desensitization

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Kidney DiseasesEnd Stage Renal Disease
Interventions
DRUG

Ixazomib Oral Capsule

Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT03213158 - Ixazomib for Desensitization | Biotech Hunter | Biotech Hunter